Showing 1,781 - 1,800 results of 171,430 for search '"5', query time: 0.23s Refine Results
  1. 1781

    The Effect of Fe Doping on the Magnetic and Magnetocaloric Properties of Mn5−xFexGe3 by Jeffrey Brock, Nathanael Bell-Pactat, Hong Cai, Timothy Dennison, Tucker Fox, Brandon Free, Rami Mahyub, Austin Nar, Michael Saaranen, Tiago Schaeffer, Mahmud Khan

    Published 2017-01-01
    “…The magnetic and magnetocaloric properties of a series of minutely doped Mn5-xFexGe3 compounds that exhibit the D88-type hexagonal crystal structure at room temperature have been investigated. …”
    Get full text
    Article
  2. 1782

    A Genetic Algorithm with Location Intelligence Method for Energy Optimization in 5G Wireless Networks by Ruchi Sachan, Tae Jong Choi, Chang Wook Ahn

    Published 2016-01-01
    “…To successfully deploy 5G network, it must be capable of handling the growth in the data traffic. …”
    Get full text
    Article
  3. 1783

    A New Trend in Cryptographic Information Security for Industry 5.0: A Systematic Review by Zaffar Ahmed Shaikh, Fahima Hajjej, Yeter Demir Uslu, Serhat Yuksel, Hasan Dincer, Roobaea Alroobaea, Abdullah M. Baqasah, Uma Chinta

    Published 2024-01-01
    “…The review covers the four main areas: 1) recognizing the need for frameworks to be developed for a secure Industry 5.0 lifecycle; 2) emphasizing security guidelines, procedures, and countermeasures for Industry 5.0; 3) applying control, access, and availability in real-time; and 4) proposing a futuristic architecture for industrial information security. …”
    Get full text
    Article
  4. 1784
  5. 1785
  6. 1786
  7. 1787
  8. 1788

    Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections by Keneth Iceland, Kasozi, Simon Peter, Musinguzi

    Published 2021
    Subjects: “…bee venom, complementary medicine and alternative medicine, SARS-CoV-2 (2019-nCoV), pharmokinetics of bee poison, COVID-19 and complementary medicine, bee venom in clinical trials…”
    Get full text
    Article
  9. 1789

    The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections by Keneth Iceland, Kasozi

    Published 2021
    Subjects: “…COVID-19 therapy; COVID-19 vaccine; COVID-19 convalescent therapy; SARS-CoV-2 infection; human antibodies; variants of concern; Ebola…”
    Get full text
    Article
  10. 1790
  11. 1791
  12. 1792

    Crystal structure of trans-N 1,N 8-bis(2-cyanoethyl)-5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane, C22H42N6 by Rabi Saswata, Dey Lucky, Rahman Ismail M. M., Tiekink Edward R. T., Roy Tapashi Ghosh

    Published 2023-08-01
    “…C22H42N6, triclinic, P 1‾ $\overline{1}$ (no. 2), a = 8.3115(2) Å, b = 8.8263(2) Å, c = 9.7688(2) Å, α = 111.490(2)° $111.490(2){}^{\circ}$ , β = 115.056(2)° $115.056(2){}^{\circ}$ , γ = 93.681(2)° $93.681(2){}^{\circ}$ , V = 583.25(3) Å3, Z = 1, R gt(F) = 0.0465, wR ref(F 2) = 0.1351, T = 294 K.…”
    Get full text
    Article
  13. 1793

    Crystal structure of rac-1,8-bis(2-carbamoylethyl)-5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane, C22H46N6O2 by Paul Pradip, Yasmin Sabina, Rabi Saswata, Rahman Ismail M. M., Tiekink Edward R. T., Roy Tapashi Ghosh

    Published 2023-08-01
    “…C22H46N6O2, triclinic, P1‾ $P\overline{1}$ (no. 2), a = 8.5777(3) Å, b = 9.0205(4) Å, c = 9.9270(3) Å, α = 67.899(3)° $67.899(3){}^{\circ}$ , β = 71.106(3)° $71.106(3){}^{\circ}$ , γ = 63.774(4)° $63.774(4){}^{\circ}$ , V = 626.83(5) Å3, Z = 1, Rgt ${R}_{\mathit{g}\mathit{t}}$ (F) = 0.0400, wRref $w{R}_{\mathit{r}\mathit{e}\mathit{f}}$ (F 2) = 0.1162, T = 298(2) K.…”
    Get full text
    Article
  14. 1794
  15. 1795
  16. 1796

    Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(−) Patients: A Comparative Meta-Analysis by Sivananthan Manoharan, Lee Ying Ying

    Published 2023-01-01
    “…Interestingly, in comparative meta-analysis, EBV(−)/SARS-CoV-2(+) patients had statistically lesser mortality (9.9%) than EBV(+)/SARS-CoV-2(+) patients (23.6%) where RR = 2.31 (95% CI: 1.34–3.99; p=0.003; I2 = 6%). …”
    Get full text
    Article
  17. 1797
  18. 1798
  19. 1799
  20. 1800